- The FDA removed the full clinical hold on Aprea Therapeutics Inc's APRE trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.
- The agency issued a clinical hold on the study in August.
- The agency's concerns referred to the safety and efficacy data from the Phase 3 myelodysplastic syndromes (MDS) clinical trial.
- A pivotal Phase 3 trial of eprenetapopt and azacitidine for the frontline treatment of TP53 mutant MDS has been completed. The trial failed to meet the primary statistical endpoint of complete remission.
- Eprenetapopt is currently on clinical hold in myeloid malignancies.
- Price Action: APRE shares are down 0.48% at $4.10 during the market session on the last check Thursday.
- Editor's Note: The story has been corrected to include 'Lymphoid Malignancies' in the headline.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in